More than a virus: a qualitative study of the social implications of hepatitis B infection in China
© The Author(s). 2017
Received: 16 March 2017
Accepted: 26 July 2017
Published: 1 August 2017
China has the largest absolute number of people living with hepatitis B with up to 300,000 people estimated to die each year from hepatitis B related diseases. Despite advances in immunisation, clinical management, and health policy, there is still a lack of accessible and affordable health care for people with hepatitis B. Through in-depth interviews, this study identifies the personal, social and economic impact of living with hepatitis B and considers the role of stigma and discrimination as barriers to effective clinical management of the disease.
Semi-structured qualitative interviews were held with 41 people living with hepatitis B in five Chinese cities. Participants were recruited through clinical and non-government organisations providing services to people with hepatitis B, with most (n = 32) being under the age of 35 years.
People living with hepatitis B experience the disease as a transformative intergenerational chronic infection with multiple personal and social impacts. These include education and employment choices, economic opportunities, and the development of intimate relationships. While regulations reducing access to employment and education for people with hepatitis B have been repealed, stigma and discrimination continue to marginalise people with hepatitis B.
Effective public policy to reduce morbidity and mortality associated with hepatitis B needs to address the lived impact of hepatitis B on families, employment and educational choices, finances, and social marginalisation.
KeywordsChina Hepatitis B Social impact Stigma Health care access Qualitative study
An estimated 93 million people live with chronic hepatitis B in China, with 300,000 people dying each year as a result of hepatitis B-related complications [1–3]. In spite of the effective implementation of the vaccination program [3–5], China experiences the highest liver cancer incidence in the world as a result of hepatitis B, which accounts for around 55% of global liver cancer deaths [6, 7].
The vast majority of people with chronic hepatitis B in China were infected at birth or in infancy . The Chinese government incorporated hepatitis B vaccination into the national planned immunization scheme for children in 2002 , with a subsequent decrease in prevalence among children younger than 1 year from 9.02% in 1992 to 0.69% in 2006. The reduction of mother to child transmission has resulted in an increase in the proportion of people infected through sexual transmission or sharing of injecting equipment, within a context of a significantly reduced number of acute infections .
Viral hepatitis has been acknowledged as an infection of global consequence. The World Health Assembly has recommended that national governments develop a strategic political response to the infection, and the World Health Organization last year released the Global Health Sector Strategy on Viral Hepatitis . This strategy provides a target of eliminating viral hepatitis as a public health threat by 2030. Given the size of the epidemic, the development of effective public policy in China that responds to the needs of people with hepatitis B will be pivotal in reaching this target.
The Chinese health system is funded through separate rural and urban health insurance systems, resulting from the 2009 health reforms. Over the past decade, China has achieved almost universal coverage of government subsidized social health insurance programs, with the share of out-of-pocket payments in total health expenditure dropping from around 50% to about 30%. However, there is no clear evidence showing a significant decline of the economic burden of patients, if any, due to rapidly inflated medical expenses  and out-of-pocket expenses remain a serious concern for access to treatment services.
Clinical management reduces the morbidity and mortality associated with the infection [10, 11]. Clinical management guidelines have been developed by the Chinese Society of Infectious Diseases and the Chinese Society for Hepatology . Despite improvements in pharmaceutical treatments there is an increasing number of hepatitis B–related deaths [13, 14] and only a small proportion of people with chronic hepatitis B access and receive treatment in China . The full range of pharmaceutical treatments listed by the American Association for the Study of the Liver are available in China, although access to the first-line drugs such as entecavir and interferon is limited by the high cost to the patient . While treatment is available through hospital-based specialist services, only 19% of people with hepatitis B have ever accessed treatment, with barriers including limited reimbursement and other costs related to testing [1, 15, 17, 18]. There is poor adherence to monitoring, with one report of only 33% of 3257 patents with hepatitis B followed up after referral . People with hepatitis B in China experience a lower quality of life than other countries given the impact of stigma and discrimination on employment, marriage and education .
Hepatitis B has been described as an economically catastrophic illness in China, with the direct costs of hepatitis B and its related diseases exceeding 40% of household annual income increasing in more advanced liver diseases . The costs are particularly significant for people with hepatitis from rural areas where it is estimated that less than 5% of patients can afford treatment for 1 year compared with approximately 40% of patients in more developed areas . A survey of disease burden in Shanghai showed that the annual direct and indirect medical costs for each patient with chronic hepatitis B were US$3000 with a per capita Gross Domestic Product at that time of around US$1000 per annum .
Hepatitis B has social implications for people living with the virus in China particularly through social marginalisation resulting from discrimination and stigma [1, 22, 23]. Regulations limiting the access of people with viral hepatitis to education and employment were passed in the late 1980s  and later repealed, when the China Ministries of Health and of Personnel announced that people with hepatitis B must not be discriminated against [25–28]. While compulsory workplace and school-based health checks that included testing for hepatitis B were cancelled in February 2010 [27, 29], testing for liver function is permitted.
This study aimed to further identify the social impact of chronic hepatitis B for people living with the infection in China. Through semi-structured interviews, we sought to understand the personal, interpersonal, economic and social consequences of the disease in the context of a rapidly changing environment. This type of investigation can provide evidence of systemic gaps and barriers that are often not apparent from clinical or epidemiological research. The experiences and needs identified by these findings can form the basis for developing effective policy and programme interventions.
How did you find out you had hepatitis B?
Who told you that you had viral hepatitis, and how were you told?
What information were you given when you were told you had hepatitis B?
Are you being treated for hepatitis B? Is your infection being monitored by a doctor or specialist?
Has finding out that you have hepatitis B changed your life? How?
What information would have been useful for you when you found out you had hepatitis B?
What other information do you need to help you deal with having hepatitis B?
Age of participants
No. of people
Interviews were electronically recorded and conducted in Mandarin through an interpreter: questions were asked in English, interpreted and responded to in Mandarin, and the response then interpreted into English. Three interviews were conducted in English at the request of the participant. Additional clarifying explanations were provided by the interpreter in consultation with the participant. The length of the interviews ranged from 25 to 90 min and interviews were transcribed by the lead investigator. To validate the interpretation, all Mandarin responses were translated using an independent translation service, with no additional findings uncovered by this process.
The analysis of the data followed the stages outlined by Braun and Clarke , with data coding and analysis conducted by the first author using a thematic analysis . The analysis began during the interviews and progressed through the careful reading of transcripts. Transcripts were initially and exhaustively coded by hand, and then entered into NVivo 10, (QSR International Pty Ltd., VIC, Australia). Themes were identified and further refined through discussion with the team. Ethical approval for the study was obtained from the La Trobe University Human Research Ethics Committee (14–006). Participation in the research was voluntary and all participants provided informed consent to their participation in the study. The interpreter signed a confidentiality agreement.
Analyses of the interviews yielded inter-connected themes. These were that hepatitis B is understood as an intergenerational family condition; that there are a substantial economic and psychological impacts as a consequence of a diagnosis of hepatitis B; disclosure was found to significantly influence employment choices; and, social marginalisation was sometimes a major issue for participants and their families.
A family disease
My parents have it, my relatives on my mother’s side have it, two of my mother’s siblings. My mother’s younger sister and younger brother and younger brother’s daughter have it. My father died of liver cancer when I was around 16 years old (Male, 25-30yo, Guangzhou).
My mother transmitted that disease to my father when they got married … my uncle also has it … besides that my grandmother has it … and my grandmother’s elder sisters (Female, 20-25yo, Shanghai).
I thought it was just one of the common diseases … in my family there were a few relatives who had this type of disease, so they think it can be treated … my mother has it, my father was a carrier, but was cured before I was born (Male, 20-25yo, Guangzhou).
My relatives were afraid of getting infected and asked me not to go to their home again (Male, 35-40yo, Guangzhou).
Sometimes, the diagnosis of hepatitis B in an individual triggered a process where other family members were tested for the virus and subsequently diagnosed. Several participants noted this had a devastating economic impact, particularly since treatment is only available through specialist services located in major cities, and where there is limited reimbursement of costs associated with treatment available.
It placed a huge financial pressure on me as my whole family had the same disease, the pressure was unbearable … my wife has to take medication, I have to take medication, my daughter has to take medication (Male, 35-40yo, Guangzhou)
This experience highlights one of several inequalities experienced by people with hepatitis B who live in rural settings, where there are very few clinical management services available.
I came from a rural area, and I was the only one in my family to have the chance to go to university. My mother was a single mother who brought me up. The reason I went to university was because I wanted to find a decent job. I had no idea how I managed to walk out of the hospital. It’s like I was hit by lightning. I didn’t dare to tell my mother (Female, 30-35yo, Guangzhou).
My health condition placed me under a lot of pressure … I couldn’t cope with a heavy workload … I had to ask my family to support me financially. I felt I betrayed their expectations (Male, 25-30yo, Beijing).
My parents were peasants; their only hope in their lifetime was for me and brother to go to university (Male, 25-30yo, Shanghai).
I need to think about my financial situation when I make decisions. I need to compare the price … I need to find out whether expensive medication is more effective than cheaper ones (Male, 30-35yo, Beijing).
I found a senior professor … after seeing my results, he recommended … anti-viral treatments. He asked me about my family’s financial situation and what type of treatment I could afford. I told him my family’s financial situation’s not very good, so he recommended me to have Lamivudine (Male, 35-40yo, Guangzhou).
As one man noted, if he was wealthy, he could have the best treatment in the world (Male, 20-25yo, Guangzhou).
The work-related impact of hepatitis B infection was significant, particularly as most participants were under the age of 35 years, for whom employment and the development of a career were key issues. While legislation in China that limited access to education and employment as a result of hepatitis B infection has been repealed, the impact of testing and a diagnosis of hepatitis B remain substantial.
I was forced to work in the small (factory), because large factories conduct health checks … To enter big factories, I might need to bribe the staff by giving them a couple thousand RMB (Male, 35-40yo, Guangzhou).
I can only find jobs with which I am not totally satisfied. The reason I came to Beijing to seek jobs was because I thought Beijing’s policy was more flexible (Male, 25-30yo, Beijing).
I only tell my close friends… there are some who still feel uncomfortable with it, but just a couple of them, not many. But the others, when they mention hepatitis in casual conversation, they seem to be very scared about it (Female, 20-25yo, Guangzhou).
I told people who are close to me and whom I used to share food with, as I don’t want to get them infected…. When we have meals together, they will serve me food to prevent me from touching the food (Female, 20-25yo, Guangzhou).
Recently I have been looking to start a relationship. I have met four or five boys but because of this disease, I was rejected by them all (Female, 25-30yo, Shanghai).
My girlfriend’s family didn’t want us to be together any more after they found out about my condition. They told my girlfriend to break up with me. But my girlfriend insisted on staying with me (Male, 25-30yo, Beijing).
You’re different. You’re a carrier … I was silent (Male, 30-35yo, Guangzhou).
I hide myself (Female, 25-30yo, Guangzhou).
I carry a burden (Male, 30-35yo, Shanghai).
I was very depressed, I was very concerned about this situation, I totally believed that I could get everybody [infected] including the people who had a close relationship with me (Male, 30-35yo, Guangzhou).
This study sought to investigate the breadth of the personal impact of hepatitis B infection, and to identify the social issues for people as they respond to the infection. These findings can be used to contribute and improve policies and programs seeking to reduce the burden of infection on people infected with hepatitis B in China.
For people in China, living with hepatitis B has extensive social as well as clinical implications. Stigma and discrimination have been identified as key social issues for people with hepatitis B in China [32–38], and who have migrated from China to other countries [35–38]. While recognising that stigma and discrimination needs to be acknowledged as an essential element in the lives of people with hepatitis B, this study sought to systematically identify how these and other social issues affected access to health services. This extends earlier survey based studies by focussing on the lived experiences as described by our participants [27, 39].
Hepatitis B was regarded as an intergenerational chronic disease. For many participants, the familial impact was a strong influence on how they responded to diagnosis and management of the virus. This relationship between their personal infection, and the experience of the infection within their family needs further investigation, particularly the impact of these experiences on accessing clinical services for the infection.
One consequence of the intergenerational and familial impact of the infection is that diagnosis of one person in the family led to other family members being diagnosed, requiring clinical intervention as a result of this diagnosis. Even when family members were not infected, a diagnosis often led to a substantial economic and social impact, particularly for people from rural areas seeking to strengthen their economic standing or where people had to relocate to access clinical services. These implications have not been noted previously, and have important implication for the management of the disease.
While hepatitis B affects individuals physically  and psychologically [40, 41], our findings extend understanding of the effects on education and employment choices. These flow on to individual and familial economic impact, career development, relationships, and residential location. These responses occur within the dynamic context of contemporary China with rapid social, cultural and economic changes.
Previous evidence of the economic impact of hepatitis B noted its significant impact [15, 21]. This study adds to the implications of this impact of individuals with hepatitis B. The economic impact of the infection are a result of policy choices by government and clinical specialists. Inadequate treatment reimbursement means that clinical choices are, for some patients, dominated by economic need.
While discriminatory regulations have been repealed, people with hepatitis B still report that their infection affects employment and educational choices, relationships and their role within society. There are a range of issues influencing the social status of people with hepatitis B including a previously recognised poor understanding of the infection among the general public and health care workers [42, 43], the poorly regulated nature of government and non-government funded clinical services, and the unsystematic testing and diagnosis of hepatitis B. The lack of accurate information within the general community affects the willingness of people with viral hepatitis to disclose their infection to friends, colleagues, and for some, their families. This essentially marginalises people with hepatitis B from participation in the wider society, and limits a person’s willingness to participate in the clinical management of the infection.
Recommendations from this study include the development of a national strategic response to hepatitis B that specifically acknowledges and addresses the social implications of the infection. The strategic response needs to recognise and respond to the impact of hepatitis B occurring within families, and the marginalisation and limited education and employment opportunities. Actions from the plan would include the provision of authoritative and consistent information campaigns targeting the general public, health care workers and people with hepatitis B, and the identification of regulations that inhibit the full involvement of people with hepatitis B within the community.
There are several limitations to this study including the representativeness of the sample, the limited number of recruitment locations, a focus on urban centres, and the use of an interpreter. Nonetheless this study generated novel and deeper understandings of the lived experience of people with hepatitis B in contemporary China. It extends the earlier work which had a clinical focus and a clinic based recruitment strategy .
Policy and programmes designed to reduce the burden of chronic viral hepatitis in China need to recognise that hepatitis B has significant social implications. A comprehensive national response to the infection needs to address the social as much as the clinical management and public health or preventive aspects of hepatitis B.
This project would not have been possible without the generosity and support of the key stakeholders and project participants interviewed in China. Key among these was the Inno Community Development Project in Guangzhou, Lei Chuang and Professors Hou, Jia and Lei. Vicki Ang is recognised for her organisational and linguistic skills.
This project was funded by the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP). CEVHAP is a non-profit organisation dedicated to public policy reform to reduce the significant health, social and economic burden of viral hepatitis in the Asia Pacific region. CEVHAP played no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.
Availability of data and materials
All data is stored in locked filing cabinets in the first author’s office and on a secured server located at La Trobe University. The data generated during the study are not publicly available for confidentiality reasons, and may be available from the corresponding author on reasonable request.
JW was the principal investigator in the study and collected all data and ethical approvals and led in the drafting of the manuscript. MP, CL, VL, BH, JR provided methodological and intellectual leadership to the study, and with SL, provided a critical review of the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Ethical approval for the study was obtained from the La Trobe University Human Research Ethics Committee (14–006). Participation in the research was voluntary, with the interpreter signing a confidentiality agreement. All participants provided informed consent to their participation in the study.
Consent for publication
All participants consented to publication.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Liu J, Fan D. Hepatitis B in China. Lancet. 2007;369:1582–3.View ArticlePubMedGoogle Scholar
- Lu FM, Li T, Liu S, Zhuang H. Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepat. 2010;17Google Scholar
- Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550–7.Google Scholar
- Zhou Y-H, Wu C, Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chinese Medical Journal. 2009;1:98–102.Google Scholar
- Cui F, Wang X, Cao L, Liang X, et al.: Progress in Hepatitis B Prevention Through Universal Infant Vaccination - China, 1997-2006. In Book Progress in Hepatitis B Prevention Through Universal Infant Vaccination - China, 1997–2006 (Editor ed.^eds.). pp. 441–445. City: U.S. Center for Disease Control; 2007:441-445.Google Scholar
- Chen W, Zheng R, Zhang S. Liver cancer incidence and mortality in China, 2009. Chinese Journal of Cancer. 2013;32:162–9.View ArticlePubMedPubMed CentralGoogle Scholar
- McDonald M, Hertz R, Lowenthal S. The burden of cancer in Asia. In: Book The burden of cancer in Asia (Editor ed.^eds.). City: Pfizer Medical Division; 2008.Google Scholar
- World Health Organization. Global Health Sector Strategy on Viral Hepatitis, 2016-2021. In: Book Global Health Sector Strategy on Viral Hepatitis, 2016–2021 (Editor ed.^eds.). City: World Health Organisation; 2016.Google Scholar
- Liu K, Wu Q, Liu J. Examining the association between social health insurance participation and patients’ out-of-pocket payments in China: the role of institutional arrangement. Social science & medicine (1982). 2014;113:95–103.View ArticleGoogle Scholar
- Lok ASF, McMahon BJ. AASLD practice guidelines; Chronic hepatitis B: Update 2009. Hepatology. 2009;50:1–36.Google Scholar
- Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348–56.Google Scholar
- Jia J. Hepatitis B in China: from guideline to practice. Virol Sin. 2008;23:152–5.View ArticleGoogle Scholar
- Chen J, Zhang S. Liver cancer epidemic in China: Past, present and future. Semin Cancer Biol. 2011;21:59–69.View ArticlePubMedGoogle Scholar
- Li Z, Wang P, Gao G, Xu C, Chen X. Age-period-cohort analysis of infectious disease mortality in urban-rural China, 1990–2010. Int J Equity Health. 2016;15:55.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun J, Hou JL: Management of chronic hepatitis B: experience from China. J Viral Hepat. 2010;17:10–7.Google Scholar
- Zheng X, Wang J, Yang D. Antiviral therapy for chronic hepatitis B in China. Med Microbiol Immunol. 2015;204:115–20.View ArticlePubMedGoogle Scholar
- Lu F-M, Zhuang H. Management of hepatitis B in China. Chin Med J. 2009;1:3–4.Google Scholar
- Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med. 2014;8:135–44.View ArticlePubMedGoogle Scholar
- Fang Q, Hao Y, Li L, Zhang Z, Wang J, Chen M, Kang J, Yang D. Chronic HBV Carrier’s acceptance of regular surveilling program in China. J Huazhong Univ Sci Technol [Med Sci]. 2013;33:288–92.View ArticleGoogle Scholar
- Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH. The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Value Health. 2008;11:527–38.View ArticlePubMedGoogle Scholar
- Lu J, Xu A, Wang J, Zhang L, Song L, Li R, Zhang S, Zhuang G, Lu M. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong China. BMC Health Serv Res. 2013;13:37.View ArticlePubMedPubMed CentralGoogle Scholar
- Li X, Xu WF. China's efforts to shed its title of “Leader in liver disease”. Drug discoveries & therapeutics. 2007;1:84–5.Google Scholar
- Yang T, Wu M-C. Discrimination against hepatitis B carriers in China. The Lancet. 2011;378:1059.Google Scholar
- Beijing Yirenping Centre. Understanding and Challenging Employment Discrimination against People Living with HBV in China. In: Book Understanding and Challenging Employment Discrimination against People Living with HBV in China. (Editor ed.^eds.). City: Beijing Yirenping Centre; 2010.Google Scholar
- Anqi L. Health Ministry to cancel hepatitis B tests for employment & school enrollment. In Book Health Ministry to cancel hepatitis B tests for employment & school enrollment. CCTV.com; 2009.Google Scholar
- Hu T, Du Q, Ren F, Liang S, Lin D, Li J, Chen Y. Spatial Analysis of the Home Addresses of Hospital Patients with Hepatitis B Infection or Hepatoma in Shenzhen, China from 2010 to 2012. Int J Environ Res Public Health. 2014;11:3143–55.View ArticlePubMedPubMed CentralGoogle Scholar
- Na L, Na B. A Revolutionary Road: An Analysis of Persons Living With Hepatitis B in China. J Health Commun. 2012;18:71–91.View ArticlePubMedGoogle Scholar
- Unattributed. Three departments further clarify hepatitis B screening item as part of pre-admission to schools/pre-employment medical examination to be cancelled. In Book Three departments further clarify hepatitis B screening item as part of pre-admission to schools/pre-employment medical examination to be cancelled. Xinhua News Agency; 2010.Google Scholar
- Ministry of Health: Notice on the further standardisation of health check up items in schooling and employment and the guarantee of the schooling and employment rights of people with hepatitis B surface antigen. In Book Notice on the further standardisation of health check up items in schooling and employment and the guarantee of the schooling and employment rights of people with hepatitis B surface antigen. Ministry of Health; 2010.Google Scholar
- Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.View ArticleGoogle Scholar
- Ryan GW, Bernard HR, Denzin N, Lincoln Y: Handbook of qualitative research. Handbook of qualitative research 2000.Google Scholar
- Ellard J, Wallace J. Stigma, discrimination and hepatitis B, a review of current research. In: Book Stigma, discrimination and hepatitis B, a review of current research (Editor ed.^eds.). City: Australian Research Centre in Sex, Health and Society, La Trobe University; 2013.Google Scholar
- Hong C, Wei Q, Cheng M, Wang X, Han Z. Illness-related stigma and its effect on interaction anxiousness and general self-efficacy in outpatients with chronic viral hepatitis. Chinese Journal of Behavioral Medical Science. 2011;(9)809-811.Google Scholar
- Pettypiece S. For Chinese, a push against hepatitis stigma. In Book For Chinese, a push against hepatitis stigma. International Herald Tribune; 2007.Google Scholar
- Cotler SJ, Cotler S, Xie H, Luc BJ, Layden TJ, Wong SS. Characterizing hepatitis B stigma in Chinese immigrants. J Viral Hepat. 2011:147–52.Google Scholar
- Carabez R, Swanner A, Yoo G, Ho M. Knowledge and fears among Asian Americans chronically infected with hepatitis B. J Cancer Educ. 2014;29:522–8.View ArticlePubMedGoogle Scholar
- Guirgis M, Nusair F, Bu YM, Yan K, Zekry AT. Barriers faced by migrants in accessing healthcare for viral hepatitis infection. Intern Med J. 2012;42:491–6.View ArticlePubMedGoogle Scholar
- Li D, Tang T, Patterson M, Ho M, Heathcote J, Shah H. The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons. Can J Gastroenterol. 2012;26:597–602.Google Scholar
- Huang J, Guan ML, Balch J, Wu E, Rao H, Lin A, Wei L, Lok AS. Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. Liver Int. 2016;36:1595–603.View ArticlePubMedGoogle Scholar
- Enescu A, Mitrut P, Balasoiu M, Turculeanu A, Enescu A. Psychosocial Issues in Patients with Chronic Hepatitis B and C. Current Health Sciences Journal. 2014;40:93–6.PubMedPubMed CentralGoogle Scholar
- Valizadeh L, Zamanzadeh V, Negarandeh R, Zamani F, Hamidia A, Zabihi A. Psychological Reactions among Patients with Chronic Hepatitis B: a Qualitative Study. Journal of caring sciences. 2016;5:57–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Feng B, Zhang J, Wei L. Inadequate awareness of hepatitis C among nonspecialist physicians in China. Advances in Medical Education and Practice. 2011;2:209–14.PubMedPubMed CentralGoogle Scholar
- Chao J, Chang E, So S. Hepatitis B and liver cancer knowledge and practices among healthcare and public health professionals in China: a cross-sectional study. BMC Public Health. 2010;10:98.View ArticlePubMedPubMed CentralGoogle Scholar